Back

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry

30 August 2024 (09:00 - 09:50)
Organised by: Logo
Congress Presentation Part of: Cancer and other risk factors for heart disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

7 More presentations in this session

Presentation thumbnail
ABO blood groups and platelet reactivity in patients with coronary artery disease undergoing percutaneous coronary intervention treated with clopidogrel
Mrs J. Li (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Ischemic and bleeding risk after ST-segment elevated myocardial infarction in patients with active cancer
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
External validation of the Systematic COronary Risk Evaluation 2 (SCORE2) model in cancer patients
Mrs M. Gynnild (Trondheim, NO)
Abstract Slides Video
Presentation thumbnail
Comparison of cardiovascular disease risk assessment tools for heart failure prediction among cancer patients
Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Cancer-specific Heart Failure (HF) risk score - a new risk score developed specifically to predict HF among cancer survivors
Professor T. Marwick (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Cancer and other risk factors for heart disease

The Event

Event poster

ESC Congress 2024

30 August 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
thumbnail
Congress Presentation
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources